Antibody Dermatology Genome Trials 
Drug Discovery World
DECEMBER 16, 2022
An immunotherapy that uses a new targeted approach to kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials. . A novel, patient-tailored monoclonal antibody therapy has shown promise in treating moderate to severe atopic dermatitis. .
Drug Discovery World
APRIL 15, 2024
The company has a biologics pipeline with a focus on differentiated antibodies targeting a range of indications. But we’ve never been able to be in that kind of design and test loop where it’s like, I have this hypothesis, I believe that if I design an antibody that has these attributes, it’s going to solve my biology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 24, 2021
With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. Read on to see. COVID-19-Related. Non-COVID-19-Related.
The Pharma Data
AUGUST 11, 2020
.–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -577 trial evaluating Opdivo (nivolumab) as an adjuvant therapy for patients with resected esophageal or gastroesophageal junction (GEJ) cancer met its primary endpoint of disease-free survival (DFS) at a pre-specified interim analysis.
The Pharma Data
AUGUST 11, 2020
The safety profiles of Opdivo and chemotherapy in this trial are reflective of the known safety profiles of Opdivo and chemotherapy in first-line gastric and esophageal cancers. The company remains blinded to data from this arm and the trial continues in follow-up to allow the data to mature. PRINCETON, N.J.–(
The Pharma Data
MARCH 11, 2021
The accelerated approval was based on tumor responses from the Phase 1/2 CheckMate -040 trial. Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types.
The Pharma Data
JULY 23, 2021
The accelerated approval was based on tumor responses from the Phase 1/2 CheckMate -040 trial. Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types.
Expert insights. Personalized for you.
52 
Let's personalize your content